Weatherford announced that it has completed its financial restructuring and emerged from chapter 11 protection. The company emerges with a stronger financial foundation having reduced approximately $6.2B of outstanding funded debt, secured $2.6B in exit financing facilities, including a $450M revolving credit facility, secured a $195M letter of credit facility, and secured over $900M of liquidity. Weatherford expects its newly issued ordinary shares will initially resume trading on the OTC Markets with the company ultimately planning to transition trading to the New York Stock Exchange, subject to the receipt of applicable approvals. The transition to the New York Stock Exchange is expected to occur after the company reports results for its fourth quarter ending December 31, holds an investor call, and completes the fresh-start accounting process, which are expected to be completed by early March.

In an interview on CNBC's Mad Money, Centene CEO Michael Neidorff said: The population we're dealing with knows us and knows what we do - they stick with us... We're the highest in quality and member satisfaction... We're growing significantly... The only way you contain costs with a single-payer system is to withhold service... Americans won't be happy with a single-payer system.

S&P Dow Jones Indices will make the following index adjustments to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 to ensure each index more appropriately represents its market capitalization range. The changes will be effective prior to the open of trading on Monday, December 23 to coincide with the December re-balance. Live Nation Entertainment (LYV), Zebra Technologies (ZBRA), and Steris (STE) will move to the S&P 500, switching places with Affiliated Managers Group (AMG), TripAdvisor (TRIP), and The Macerich Co. (MAC), respectively. All companies moving to the S&P 500 have market capitalizations above $12B, and all companies moving to the S&P MidCap 400 have market capitalizations below $4.5B. Grand Canyon Education (LOPE) and Lear (LEA) will replace Oasis Petroleum (OAS) and Southwestern Energy (SWN) in the S&P MidCap 400 respectively. Oasis Petroleum and Southwestern Energy will replace Unit Corp. (UNT) and Frontier Communications (FTR) in the S&P SmallCap 600. Oasis Petroleum and Southwestern Energy are more representative of the small-cap market space, while Unit and Frontier Communications are no longer representative of the small-cap market space. Arrowhead Pharmaceuticals (ARWR) will switch places with Granite Construction (GVA) in the S&P MidCap 400. Arrowhead Pharmaceuticals has a market capitalization more representative of the mid-cap market space, and Granite Construction has a market capitalization more representative of the small-cap market space.

In an interview on CNBC's Mad Money, Anaplan CEO Frank Calderoni said: We've had four quarters since the IPO where we've been able to grow the top and bottom lines... Digitization has really started to accelerate and it's driving our results... We're increasing the number of new customers and current customers are spending more with us... The new world is all about real-time planning.. Over the next five years there's going to be a dramatic shift in planning.

In a regulatory filing, Harmonic disclosed that its CFO Sanjay Kalra sold 28K shares of common stock on December 11th. The total transaction size was $229K.

Horizon Pharma up 9.6% to $36.00 after FDA unit supports use of teprotumumab

Amarin rises 1.4% to $24.46 after resuming trading

Arrowhead to replace Granite Construction in S&P 400 at open on 12/23

Oasis Petroleum (OAS) and Southwestern Energy (SWN) will replace Unit Corp. (UNT) and Frontier Communications (FTR) in the S&P SmallCap 600.

Grand Canyon Education (LOPE), and Lear (LEA) will replace Oasis Petroleum (OAS) and Southwestern Energy (SWN) in the S&P MidCap 400, respectively.

Raytheon was awarded a $123.53M firm-fixed-price and cost-plus-fixed-fee modification to previously awarded contract to exercise options for FY20 production of AEGIS weapon system fire control system, or FCS, MK 99 equipment, AEGIS modernization production requirements and associated engineering services. These services are in support of DDG 51 Class Flight III destroyers and the Spanish navy's F-110 program. This modification also covers the production of the AEGIS BMD kill assessment ordnance alteration kits and solid state switch assembly special test equipment. The AMOD program fields combat system upgrades that will enhance the anti-air warfare and ballistic missile defense capabilities of AEGIS equipped DDG 51 Arleigh Burke-class destroyers. Work is expected to be completed by April 2023. Foreign Military Sales; FY20 shipbuilding and conversion;FY20 other procurement and FY20 defense wide procurement funding in the amount of $123.53M will be obligated at the time of award and will not expire at the end of the current fiscal year. The Naval Sea Systems Command is the contracting activity.

BAE Systems was awarded a $249.15M modification to a contract for the self-propelled Howitzer and carrier, ammunition, tracked vehicles and their associated support under the production contract to build and deliver M109A7s and M992A3s. Work will be performed in York, Pennsylvania, with an estimated completion date of January 31, 2023. FY18 and FY19 other procurement, Army funds in the amount of $249.15M were obligated at the time of the award. U.S. Army Contracting Command is the contracting activity.

On December 10, 2019, the company's board authorized a share repurchase program for calendar-year 2020 authorizing the repurchase of up to 848,000 shares of the company's common stock from time to time on the open market or in privately-negotiated transactions. The share repurchase program is expected to be completed by December 31, 2020. The company's previously-authorized share repurchase program will expire on December 31, 2019.

iBio, Inc. announced that on December 9, 2019, the company received a letter from NYSE American LLC indicating the company's securities have been selling for a low price per share for a substantial period of time and pursuant to Section 1003fv of the NYSE American Company Guide, the company's continued listing on the Exchange is predicated on the company effecting a reverse stock split or otherwise demonstrating sustained improvement in its share price within a reasonable period of time, which the Exchange has determined to be no later than June 9, 2020. Additionally, the company does not currently meet certain other NYSE American continued listing standards as set forth in Part 10, Section 1003(a)(i), (ii) and (iii) of the Company Guide, due to the fact the company had reported stockholders' equity of less than $6.0M, as of September 30, 2019, and net losses in its five most recent fiscal years.

Bio-Rad Laboratories announced that the company is making good progress recovering from a ransomware attack that was detected on Bio-Rad's network on December 5, 2019. The Bio-Rad website and telephone communications have been brought back online. Bio-Rad is continuing to restore affected systems and return to normal operations and the company has resumed taking orders and shipping product.

Amarin announced that the FDA has approved a new indication and label expansion for Vascepa capsules. After more than a decade of development and testing, Vascepa is now the first and only drug approved by the FDA "as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride levels and established cardiovascular disease or diabetes mellitus and two or more additional risk factors for cardiovascular disease." It is estimated that millions of high-risk patients in the United States could benefit from this one-of-a-kind prescription therapy.